ImmuDyne: Second Patent Issued for Topical Treatment of Hair Loss/Alopecia; Q1 Launch Scheduled
January 24 2017 - 7:00AM
ImmuDyne (OTCQB:IMMD), a leader in the development and marketing of
OTC health and wellness products addressing large unmet needs,
today announced the issuance of a 2nd Patent relating to the
topical treatment of hair loss/alopecia. The invention also
provides methods for use:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9532941.PN.&OS=PN/9532941&RS=PN/9532941
In September 2016, Immudyne reached a definitive agreement with
Pilaris Laboratories, LLC (“Pilaris”), for a sole and exclusive
worldwide license to commercialize the patented PilarisMax line of
hair loss products. Pilaris was founded by two prominent
dermatologists, Steven D. Shapiro M.D. and Michael T. Borenstein
M.D. Ph.D. after 5 years of clinical research on topical
dihydrotestosterone (DHT) inhibitors. Dr. Shapiro has over 20 years
of clinical experience with treating hair loss and hair transplant
procedures. Dr. Borenstein holds a Ph.D. in Pharmacology and has a
background in scientific research in addition to over 12 years of
clinical dermatology practice.
Branding is now completed, and the products will now launch
under the Shapiro M.D. label. Steven Shapiro M.D. stated, “We
are very impressed with the work put in by ImmuDyne. Our collective
goal is to become a leading brand in the men’s and women’s hair
loss category.”
The official launch date of Shapiro M.D. should occur in Q1 and
will be announced soon.
About lmmuDyne
lmmuDyne, Inc. (the "Company") is a health and wellness company
which develops, manufactures, markets, and sells innovative
lifestyle products. The Company's lead products contain its
proprietary yeast beta glucans that have been shown through testing
and analysis to support the immune system. The Company's products
include once a day oral intake capsules as well as topical serums
and creams for skin application. lmmuDyne also has developed a
proprietary natural delivery technology for potential new market
opportunities. All of lmmuDyne's intellectual property is protected
by patents and/or trade secrets. Additional information can be
found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe
Harbor Act Disclaimer: Forward looking statements in this release
are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. Certain statements in
this press release, including projections with respect to
lmmuDyne's results of operations, may contain words such as
"anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "projects," "plans," "targets" and other similar
language and are considered forward-looking statements. These
statements are based on management's current expectations,
estimates, and forecasts. These forward-looking statements are
subject to important assumptions, risks and uncertainties, which
are difficult to predict and therefore the actual results may be
materially different from those discussed.
Contact:
lmmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901